Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMINDERA early rheumatoid arthritis remission induction and tapering study
NL-OMON47431Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of golimumab, methotrexate, hydroxychloroquine and methylprednisolone in rheumatoid arthritis (RA) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Sustained remission at week 24 after start of tapering. Started May 2017; status: active, not recruiting.
02
Drugs
golimumabmethotrexatehydroxychloroquinemethylprednisolone
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON47431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47431.